Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Mizuho Medy Co's annualizedNet Income for the quarter that ended in Dec. 2025 was 円0 Mil. Mizuho Medy Co's average total tangible assets for the quarter that ended in Dec. 2025 was 円20,954 Mil. Therefore, Mizuho Medy Co's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 0.00%.
The historical rank and industry rank for Mizuho Medy Co's Return-on-Tangible-Asset or its related term are showing as below:
TSE:4595'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.11 Med: 17.21 Max: 52.87
Current: 4.11
During the past 12 years, Mizuho Medy Co's highest Return-on-Tangible-Asset was 52.87%. The lowest was 4.11%. And the median was 17.21%.
TSE:4595's Return-on-Tangible-Asset is ranked better than 54.71% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.13
vs TSE:4595: 4.11
Mizuho Medy Co (TSE:4595) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Mizuho Medy Co Return-on-Tangible-Asset Related Terms
Mizuho Medy Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Mizuho Medy Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4595 vs ZTS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Mizuho Medy Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mizuho Medy Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mizuho Medy Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Mizuho Medy Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 0.00% mean?
Mizuho Medy Co (TSE:4595) has a Return-on-Tangible-Asset of 0.00% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mizuho Medy Co and its competitors. Over the past decade, Mizuho Medy Co's Return-on-Tangible-Asset has ranged from 4.11 to 52.87. According to the industry distribution chart, Mizuho Medy Co ranks #457 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 45.3%.
Is Mizuho Medy Co's Return-on-Tangible-Asset too high?
Mizuho Medy Co's current Return-on-Tangible-Asset is 0.00%. Over the past 10 years, this metric has ranged from a low of 4.11 to a high of 52.87. Based on the distribution chart, Mizuho Medy Co ranks #457 out of 1009 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mizuho Medy Co has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mizuho Medy Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mizuho Medy Co ranks #457 out of 1009 companies for Return-on-Tangible-Asset. This puts Mizuho Medy Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.13. Historically, Mizuho Medy Co's own Return-on-Tangible-Asset has ranged from 4.11 to 52.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.13, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Mizuho Medy Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mizuho Medy Co's current Return-on-Tangible-Asset is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mizuho Medy Co stock overvalued right now?
Based on GuruFocus' analysis, Mizuho Medy Co (TSE:4595) is currently considered Modestly Overvalued. The stock's GF Value™ is 円1,434.04, compared to a current price of 円1,677.00 — trading 16.9% above its estimated fair value. The current Return-on-Tangible-Asset is 0.00%. Mizuho Medy Co's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Mizuho Medy Co (TSE:4595), the current Return-on-Tangible-Asset is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mizuho Medy Co (TSE:4595) Overvalued in 2026?
Based on GuruFocus' analysis, Mizuho Medy Co stock appears to be overvalued.
The current stock price of 円1,677.00 is trading 16.9% above its estimated GF Value™ of 円1,434.04.
GuruFocus considers Mizuho Medy Co to be Modestly Overvalued.
Key valuation signals for TSE:4595:
Return-on-Tangible-Asset: 0.00%
GF Value™: 円1,434.04 vs. price of 円1,677.00 (16.9% above fair value)
No single metric tells the full story. See the TSE:4595 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mizuho Medy Co Ltd engages in research and development, manufacture, and distribution of in-vitro diagnostic products. The company provides immuno assay test products, such as influenza virus kits; Infectious diseases test kits; fecal occult blood test kits for detection of human hemoglobin and human transferrin in feces; and biochemical liquid stable reagents for professionals. It also offers HCG (midstream test), including a digital p-check test for OTC. It also offers fruit tree virus test drugs to agricultural testing places.
84GF Score
Get the complete analysis for TSE:4595
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4595 has been successfully added to your 
